Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
63.97 USD | -0.84% | +0.52% | -17.03% |
01:00pm | Bio-Techne Corporation Appoints Dr. Judith Klimovsky to Board of Directors | CI |
04-29 | Bio-Techne to Enter Product Distribution Deal With Thermo Fisher Scientific | MT |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an expected P/E ratio at 58.12 and 45.43 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.03% | 10.14B | B+ | ||
+0.71% | 42.86B | B | ||
+12.22% | 42.74B | B- | ||
+44.30% | 41.36B | A | ||
-6.20% | 27.68B | C | ||
+6.43% | 25.15B | B- | ||
-23.57% | 18.63B | B | ||
+28.00% | 12.37B | C+ | ||
-3.09% | 11.92B | C+ | ||
+7.30% | 11.21B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TECH Stock
- Ratings Bio-Techne Corporation